Files and links (1)
Published, Version of Record (VoR)CC BY V4.0, Open
Journal article
SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class
BMC endocrine disorders, Vol.19(1), 64
17 Jun 2019
PMID: 31208401
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME.
To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence.
CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.
Metrics
1 Record Views
Details
- Title
- SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class
- Creators
- Guntram Schernthaner - Department of Medicine I, Rudolfstitung Hospital, Vienna, Austria. guntram.schernthaner@meduniwien.ac.atHeinz Drexel - Vorarlberg Institute for Vascular Investigation and TreatmentEvgeny Moshkovich - Unit of Endocrinology and Metabolism, Sapir Medical Center, Kfar-Saba, IsraelBirute Zilaitiene - Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, LithuaniaEmil Martinka - National Institute of Endocrinology and Diabetology, Lubochna, SlovakiaLeszek Czupryniak - Department of Diabetology and Internal Medicine, Warsaw Medical University, Warsaw, PolandTamás Várkonyi - 1st Dept of Internal Medicine, University of Szeged, Szeged, HungaryAndrej Janež - Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, SloveniaKristine Ducena - Division of Endocrinology, Faculty of Internal Medicine, University of Latvia, Riga, LatviaKatarina Lalić - Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Beograd, SerbiaTsvetalina Tankova - Clinical Centre of Endocrinology, Medical University - Sofia, Sofia, BulgariaMartin Prázný - Diabetes Centre, Charles University and General Faculty Hospital, Prague, Czech RepublicLea Smirčić Duvnjak - School of Medicine, University of Zagreb, Vuk Vrhovac University Clinic-UH Merkur, Zagreb, CroatiaOlga Sukhareva - Endocrinology Research Centre, Moscow, Russian FederationHarald Sourij - Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
- Publication Details
- BMC endocrine disorders, Vol.19(1), 64
- Number of pages
- 13
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000471860600002
- Scopus ID
- 2-s2.0-85067579055
- Other Identifier
- 991021860790404721
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Endocrinology & Metabolism